Bristol-Myers Squibb, AstraZeneca present analysis of dapagliflozin studies

PRINCETON, N.J. — Bristol-Myers Squibb and AstraZeneca presented an analysis Wednesday of 14 clinical trials at the American Heart Association's Scientific Sessions in Orlando, Fla., the companies said.



The phase-2b and phase-3 trials all involved the investigational Type 2 diabetes drug dapagliflozin and, the companies said, showed that use of the drug did not lead to an unacceptable risk to adult patients' cardiovascular health compared with other treatments.



The analysis included 6,228 patients, with 4,287 taking dapagliflozin and 1,941 taking other drugs.



"This comprehensive analysis provides valuable information that can be used to better understand cardiovascular safety profile of dapagliflozin as a monotherapy or as an add-on therapy to common antidiabetic treatments," Bristol-Myers Squibb SVP global development and medical affairs Brian Daniels said.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.